Skip to main content
IMS Events Main banner

  1. Home

  • Friday, Sep 27th
    2:04 PM – 2:24 PM East Coast USA Time
    OA - 63: Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
    Location: Plenary Hall, Pavilion 3
    Speaker: Saad Z. Usmani, MD MBA – Memorial Sloan Kettering Cancer Center
    Plenary Discussion